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Unstructured summary 
The aims of this Oncoplastic Breast Consortium (OPBC) initiative were to identify important 
knowledge gaps in the field of oncoplastic breast-conserving surgery (OPS) and nipple- or skin-
sparing mastectomy (NSM/SSM) with immediate reconstruction and to recommend appropriate 
research strategies to address them. A total of 212 surgeons and 26 patient advocates from 55 
countries prioritised the fifteen most important from a list of 38 identified knowledge gaps in two 
electronic Delphi rounds. An interdisciplinary OPBC panel of 63 stakeholders from 20 countries 
obtained consensus during an in person meeting to select seven of these fifteen knowledge gaps as 
research priorities: Firstly, the impact of OPS on quality of life and the optimal type and timing of 
reconstruction after NSM/SSM with planned radiotherapy should be addressed by prospective cohort 
studies at an international level. Secondly, the role of adjunctive mesh and the positioning of implants 
during implant-based breast reconstruction should ideally be investigated by randomised controlled 
trials of pragmatic design. Thirdly, BREAST-Q is a suitable tool to assess primary outcomes in these 
studies, but other patient reported outcomes metrics should be systematically evaluated and quality 
indicators of surgical morbidity further assessed. 
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Introduction 
The emphasis on aesthetic outcomes and quality of life (QoL) after breast cancer treatment motivated 
surgeons to develop oncoplastic breast surgery, which includes oncoplastic breast-conserving surgery 
(OPS), as well as nipple-sparing mastectomy (NSM) and skin-sparing mastectomy (SSM) with 
immediate reconstruction.  The first oncoplastic breast surgery techniques were introduced into 
clinical practice over 25 years ago.1-3 Nevertheless, current evidence is based mainly on single-centre 
observational studies with small sample sizes and short follow up. Applicability and generalisability of 
study findings in the field of OPS are further limited by the lack of robust study designs and the 
complex issue of standardisation of these tailored surgical techniques.4 Even though NSM and SSM in 
conjunction with a wide range of options for immediate reconstruction are considered more 
standardised procedures, many open questions remain when applying them in clinical practice.5 Large 
single-centre series with extended follow-up, prospective multi-centre studies and randomised 
controlled trials (RCTs) have only recently been published in this important field.6-8  
In the past few years, several organisations have systematically evaluated and specified current areas for 
improvement in surgical breast cancer research and treatment. The Association of Breast Surgery Gap 
Analysis Working Group described various key research gaps including the need to assess the 
effectiveness of oncoplastic and reconstructive surgery.9 The gap analysis identified several ongoing 
controversies that need to be resolved in this clinical field. The Swiss, German and Austrian societies of 
senology convened a consensus conference that revealed substantial heterogeneity in several aspects of 
clinical OPS practice.10 Finally, the global Oncoplastic Breast Consortium (OPBC) has identified major 
disagreement among experts in many questions that are pertinent to NSM with immediate 
reconstruction.11 
The aims of this consensus process were to identify the most important knowledge gaps in the field of 
oncoplastic breast surgery based on the integration of all types of clinical evidence including 
experience drawn from contemporary practice and to propose appropriate and practical scientific 
strategies to address them. 
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Methods 
List of knowledge gaps 
The identification of knowledge gaps was performed according to a pre-specified protocol (pages 2-8, 
supplementary material), as follows: All knowledge gaps were included that were identified by 
significant disagreement (≥25%) among experts during the first international consensus conference on 
OPS10 and the first OPBC consensus conference on NSM11. The seven scientific secretaries were 
tasked with adding key knowledge gaps in oncoplastic breast surgery practice and research to this list 
based on their expert opinion. All 424 OPBC members were informed via a newsletter of the 
upcoming Delphi process and were able to give feedback, as well as report additional knowledge gaps. 
In order to identify key literature in the field that may indicate whether a knowledge gap had already 
been well addressed, two scientific secretaries performed a specific PubMed search in January 2019 
using search terms related to research needs and nipple- or skin-sparing mastectomy and OPS (search 
strategy: “inconclusive”[tiab] OR “unknown”[tiab] OR "further research"[tiab] OR "research 
need"[tiab] OR “gap”[tiab] OR “priority”[tiab] OR “unmet”[tiab]) AND “skin AND mastectomy” OR 
“nipple AND mastectomy” OR ("mammaplasty"[Mesh]) OR (“oncoplastic” OR "oncoplastic surgery" 
OR "oncoplastic technique" OR "oncoplastic breast conservation" OR "oncoplastic breast reduction" 
OR "oncoplastic breast surgery" OR "oncoplastic approaches" OR "oncoplastic techniques") OR 
("therapeutic mammaplasty" OR mammaplasties OR mammoplasty OR mammoplasties) OR ("breast 
conserving surgery" OR "partial breast reconstruction" OR "conservative breast surgery" OR "Breast 
Conservation Therapy" OR "oncoplastic approach"[tiab]). The same two scientific secretaries queried 
clinicaltrial.gov (using search terms “breast cancer” for condition/disease and “nipple-sparing” or 
“skin-sparing” or “oncoplastic”) to obtain information on ongoing clinical trials indicating that 
knowledge gaps may be sufficiently addressed in the near future. The scientific secretaries adjusted 
and finalised the list of knowledge gaps. 
Delphi process 
The prioritisation of knowledge gaps was performed according to a pre-specified Delphi process 
(pages 3-4, supplementary material). Two rounds of electronic surveys were sent to all OPBC 
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members to assess the importance of knowledge gaps with anonymised feedback of results. 
Importance was defined as need for knowledge to guide clinical practice and research, as opposed to 
knowledge of theoretical or purely scientific interest.  
A personalized access link for the electronic round-one questionnaire was sent out on 24 April 2019 to 
all 390 surgeons and 34 patient advocates of the OPBC according to the pre-specified timeline. Soon 
thereafter, several recipients raised concerns about the comprehensibility of the questionnaire for the 
patient advocates. Therefore, additional lay term explanations for all questions and a glossary prepared 
by scientific secretaries and a patient advocate (with 30 years of experience in healthcare 
communication) were sent to all patient advocates.  
Participating members were asked to rank the importance of every knowledge gap on a nine-point 
Likert scale from one (not important) to nine (extremely important) and to recommend ten of them as 
OPBC research priorities (pages 9-10, supplementary material). A time frame of 2.5 weeks was 
permitted for submission of the questionnaire with two reminders sent during that time.  
All participants from the first round received a second personalised access link to the electronic round-
two questionnaire. First-round non-responders were considered to have declined study participation 
and were not contacted again for the second round. The round-two questionnaire consisted of the same 
list of knowledge gaps with aggregated feedback from round one. Feedback included the percentage of 
participants recommending the topic for inclusion in the OPBC research agenda and the median Likert 
ranking of each item of round one, shown separately for medical professionals, patient advocates and 
all participants (page 11, supplementary material). Participants were asked to complete the 
questionnaire again to review, re-rate and re-prioritise the knowledge gaps in light of the above 
feedback and their own answers to the first round displayed for each knowledge gap. A period of two 
weeks was permitted to complete round two with two reminders again being sent.   
To take account of the preferences of all participating medical professionals and patient advocates, 
results from round one were used in the final analysis for those participants who did not take part in 
round two. The proportion of recommendations for inclusion in the OPBC research agenda and the 
median Likert rating of each knowledge gap were calculated separately for medical professionals and 
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patient advocates. The mean of the proportion of recommendations and Likert ratings for the two 
groups was used for ranking of the knowledge gaps. Ranking was determined first by descending 
proportion of recommendations and second by descending Likert rating. The top 15 ranked knowledge 
gaps were selected to be discussed at the OPBC consensus conference as potential research priorities.  
Delphi participants 
There are currently no guidelines for the numbers of participants required for such a Delphi process. 
Given the complexity of identifying knowledge gaps in clinical practice and research in the field of 
oncoplastic surgery, we planned a priori to recruit a heterogeneous group of specialized surgeons and 
patient advocates for the process. Firstly, we pre-specified a minimum number of 85 OPBC surgeons 
from around the world with diversity in terms of background, career-stage, gender, and geography, 
representing clinicians who perform oncoplastic surgery in daily practice. Secondly, we planned to 
recruit a minimum of 15 OPBC patient advocates from different countries. The OPBC reflects a 
heterogeneous consortium of specialists and patient advocates. A first group of OPBC members 
consists of national coordinators and panellists who have permanent roles within the OPBC. They 
were invited to join the OPBC based on their expertise in breast cancer management with a practice 
primarily dedicated to management of breast cancer.11 A second group of OPBC members consists of 
breast surgeons from various backgrounds with different levels of experience who decided to join the 
OPBC by self-registration on the OPBC website.12 The OPBC patient advocacy group consists of 
patients who underwent breast cancer surgery with or without partial or whole breast reconstruction 
and volunteered to support the mission of the OPBC. A questionnaire was sent to all OPBC members 
during the Delphi process to evaluate their background characteristics. 
Consensus conference 
The consensus conference panel consisted of 63 special guests, OPBC panellists and OPBC patient 
advocates from 20 countries (pages 12-15, supplementary material). Special guests were selected 
based on their expertise in medical oncology, radiation oncology, clinical epidemiology or biostatistics 
with representation from research support units and surgical trainees. The latter responded to a call for 
trainees in an OPBC newsletter. 
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Prior to the conference, the 15 top-rated knowledge gaps identified during the Delphi process were 
sent to the panel with detailed voting results (exact percentage and mean score). The panel met face to 
face to agree on the list of research priorities and to discuss the most appropriate study designs. Since 
many of the knowledge gaps were broad-based topics in the field of OPS and NSM/SSM with 
immediate reconstruction, more focused research questions were developed in the PICO (Patient 
problem, Intervention, Comparison, and Outcome) format.13 This allowed the evaluation of research 
tools and/or clinical trial designs to address knowledge gaps most appropriately. The degree of 
appropriateness was assessed according to the methodological quality of the study design, its 
feasibility and the expected applicability of results to the respective knowledge gaps. The scientific 
secretaries prepared a concise strategy proposal incorporating both the research question and trial 
design to address the 15 most important knowledge gaps. The proposal was sent to the panellists in 
advance and served as basis for discussion during the meeting (pages 16-33, supplementary material).  
After two lectures on selection and prioritisation of knowledge gaps, voting on the top 15 identified 
during the Delphi process took place to determine which of these should become OPBC research 
priorities (page 34, supplementary material). Voting was in the format yes, no or abstain. Simple 
majority was defined by agreement among 51–75% of the panellists and consensus by agreement 
above 75%. In case of consensus to add a knowledge gap to the agenda, the proposed strategy to 
address this gap was discussed and adjusted live on screen according to the comments of the panel, 
followed by voting on the strategy (page 35, supplementary material). In case of majority voting on 
the knowledge gap or respective scientific strategy, discussion and re-voting was encouraged.  
Search strategy and selection criteria The results of the Delphi process and consensus conference were 
brought into context with published, ongoing or planned studies in the form of this review. Literature 
searches were developed, peer-reviewed and conducted by two information specialists. Medline (via 
Ovid), Embase (via Elsevier) and Epistemonikos were searched for RCTs, systematic reviews and meta-
analyses using text words and subject headings for terms around breast cancer/mastectomy and breast 
reconstruction/OPS, and standardized filters for study designs were applied.14,15 To identify any planned 
or ongoing studies, Prospero, ClinicalTrials.gov and the WHO International Clinical Trials Registry 
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Platform were searched (see pages 36-39, supplementary material for full strategy). In a first screening 
round performed on abstract level, references were excluded by one author (AS) according to the 
following criteria: study not involving humans, study not on breast cancer, study on basic research only, 
study without surgical intervention, study on the antibiotic effect of compounds only, study on 
drains/sealing/dressing only, study on decision aids for patients, study on cost analysis only. A second 
screening round was performed independently by two authors (GM and EK) on abstract level and 
references were further selected according to their relevance in respect of the seven selected research 
priorities. These references were added with full-text to an EndNote X8 library. Finally, the first author 
(WPW) generated the final reference list from this EndNote X8 library based on currentness and 
relevance to the scope of this review. Additional references cited within those publications or retrieved 
from personal files were selectively included. 
 
 
  
 10 
 
Findings 
A total of 38 knowledge gaps were identified in the field of oncoplastic surgery (table one). During 
Delphi round one, knowledge gaps were prioritised by 54% (212/390) of OPBC surgeons and 76% 
(26/34) of OPBC patient advocates who came from 55 countries (see page 40 of supplementary 
material for characteristics and pages 41-42 for countries of Delphi participants and pages 43-50 for 
full results of Delphi process). These figures were well above the pre-specified minimum number of 
Delphi participants requested in the protocol. During Delphi round two, knowledge gaps were re-
prioritised by 80% (170/212) of OPBC surgeons and 77% (20/26) of patient advocates. As pre-
specified in the protocol, feedback from round one was used for the 20% (42/212) of professionals and 
23% (6/26) of patient advocates who completed round one but did not complete round two.  
One question was not ranked among the 15 most important knowledge gaps by medical professionals, 
but was included due to high ranking by patient advocates. Two questions were not ranked among the 
15 most important knowledge gaps by patient advocates, but were included due to high ranking by 
medical professionals. One of these questions was included in the 15 most important knowledge gaps 
only by re-prioritisation during round two. 
The seven OPBC research priorities selected by consensus during the conference are shown in table 2. 
The iterative discussion and voting process (page 51, supplementary material) achieved consensus on 
the appropriate research method to address six of the research priorities and a strong majority for one 
(table 3). The selected research priorities and proposed study designs are discussed below.  
What is the optimal type of reconstruction in the setting of planned adjuvant radiotherapy? 
This top-ranked knowledge gap was selected as a research priority by 98% of conference participants 
and the corresponding research question in the PICO format was readily accepted as well.13 However, 
the most appropriate research strategy was heavily debated. A RCT design, as suggested by the 
scientific secretaries, was not felt to be feasible and the study design selected was a prospective cohort 
study with propensity score matching and patient-reported satisfaction with breast, assessed by the 
BREAST-Q questionnaire at two years, as the primary outcome. This design was endorsed by more 
than three-quarters (79%) of panellists.  
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What is the optimal timing of reconstruction in the setting of planned adjuvant radiotherapy? 
This knowledge gap was ranked second during the Delphi and was added to the OPBC research 
agenda with strong consensus at initial voting during the conference. While the corresponding PICO 
question was also promptly accepted, the discussion on the study design mirrored the previous one. 
Re-voting achieved consensus on a prospective register to optimally address the first two knowledge 
gaps. 
What are the indications for the use of synthetic versus biological versus no mesh in implant-based 
breast reconstruction? 
This knowledge gap ranked fifth in the Delphi process and was only selected as a research priority by 
re-voting after discussing the limitations of any particular study design to specifically evaluate 
indications of one versus another device. The panel agreed to address this knowledge gap with a 
research question focusing on patient satisfaction with initial use of any type of mesh, as opposed to 
comparing different types of mesh. It recommended a pragmatic non-inferiority RCT design with the 
BREAST-Q “satisfaction with breast” scale as a long-term patient reported primary outcome, stratified 
by breast size and degree of ptosis. 
What are the indications for the use of pre- vs sub-pectoral implant-based breast reconstruction? 
This was the first knowledge gap to be unanimously accepted as an OPBC research priority and also to 
achieve a consensus recommendation for the most appropriate research question and trial design at 
initial voting. The panel recommended a pragmatic superiority RCT to address the question of whether 
patients undergoing pre-pectoral IBBR are more satisfied than patients undergoing sub-pectoral IBBR.  
What is the effect of OPS on quality of life?  
The panel added this knowledge gap to the agenda with a prompt consensus recommendation to 
address it by a prospective multi-centre cohort study with propensity score matching and the 
BREAST-Q “satisfaction with breast” scale as primary endpoint. 
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What are the best tools to measure the effect of OPS on quality of life and to allow comparison of trial 
results? 
The panel included this knowledge gap in the OPBC research agenda with direct consensus at initial 
voting. It recommended a similar method to the one used for the present review, consisting of a Delphi 
process with development based on a systematic review or even meta-analysis followed by a 
consensus conference. Both of these components should involve patient advocates. 
What are the most accurate quality indicators in OPS?  
Despite significant overlap between this and previous knowledge gaps, the panel accepted it as a 
research priority since aesthetic results and QoL are not the only relevant quality indicators. The panel 
discussed how the disadvantages of OPS should be monitored, especially since OPS reflects a clear 
escalation of surgery compared to conventional BCS (see figure one for example of a common OPS 
procedure). Hence, the morbidity associated with OPS is likely to be increased. The panel 
recommended the risk of complications to be further evaluated in prospective multi-centre cohort 
studies before deciding on the most accurate quality indicators in OPS. 
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Discussion 
The present process identified several important knowledge gaps in the field of oncoplastic breast 
surgery and resulted in recommendations for appropriate research strategies to approach them. The 
optimal type and timing of reconstruction after NSM/SSM with planned radiotherapy were considered 
the most important knowledge gaps and correspond to areas of controversy in the literature. 
Radiotherapy has a major impact on the risk of complications after immediate implant-based breast 
reconstruction (IBBR) as well as autologous breast reconstruction.16,17 A large prospective multi-
centre cohort study compared complications and PROs of irradiated and non-irradiated patients who 
received reconstruction.18 Autologous reconstruction, which is often not offered by reconstructive 
surgeons in this context, was associated with lower risk of complications and higher patient 
satisfaction compared to IBBR. Other series have confirmed these observations, but major controversy 
persists concerning the use of immediate autologous reconstruction in this setting.19-23 Indeed, several 
large series have shown good outcomes after immediate IBBR in the context of radiotherapy as well, 
with different timing strategies for two-stage immediate IBBR.24,25 The recommended OPBC studies, 
together with other planned or ongoing prospective observational studies and even RCT’s, will help 
select the optimal type and timing of reconstruction when radiotherapy is planned.26-29 Finally, 
preoperative radiotherapy has gained renewed interest as strategy to reduce the risk of radiation-
induced toxicity to the reconstructed breast.30  Several observational studies with long-term follow-up 
suggest that the concept of radiotherapy followed by mastectomy with or without immediate breast 
reconstruction is oncologically safe.31-33   
The present work further identified the role of adjunctive mesh and positioning of implants in relation 
to the pectoral muscle during IBBR as important knowledge gaps. The availability of acellular dermal 
matrix (ADM) and synthetic meshes for soft tissue coverage has triggered increased usage of one-
stage immediate IBBR and subsequently pre-pectoral approaches.34-40 To date, all published studies on 
pre-pectoral IBBR are small and observational, mostly suggesting that it is safe and effective.35-37,41-44 
Sub-pectoral IBBR, however, remains the most commonly performed breast reconstruction in the 
US.45 Several prospective studies are planned or ongoing to assess the role of adjunctive mesh in 
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different settings.46-48 Three RCTs comparing pre- versus sub-pectoral approaches for immediate 
IBBR are registered: a tri-centre trial in Denmark and Norway49 and single-centre trials from the Mayo 
Clinic50 and Ottawa Hospital Research Institute.51  The OPBC recently received major public funding 
from the Swiss National Science Foundation for OPBC-02 / PREPEC, a large international RCT on 
pre- versus sub-pectoral IBBR after NSM or SSM.52 It will test the hypothesis that pre-pectoral IBBR 
is associated with improved long-term QoL. The primary endpoint will be patient-reported chest 
physical well-being measured by the BREAST-Q. The trial will include 372 patients across 21 OPBC 
sites in seven countries with 24 months of follow-up. Randomisation of the first patient is planned for 
June 2020. The trial was designed by applying the PRECIS-2 requirements for pragmatism, which is 
in line with the current panel recommendation.53-56 The study design allows surgeons much flexibility 
in the technical aspects of surgical decision-making. This may help avoid some of the safety issues 
encountered in the BRIOS trial.7,8 Although the latter revealed no major differences in patient QoL and 
satisfaction when comparing one- versus two-stage immediate IBBR, the ADM-assisted one-stage 
approach was associated with significantly higher odds of complications, re-operation, as well as loss 
of implant, ADM or both. Despite these high rates of complications being partly explained by poor 
patient selection and lack of experience with a one-stage technique, its safety in routine surgical 
practice must be questioned.57,58  
Finally, the aforementioned process identified the need to investigate the effectiveness of OPS. The 
association between objective aesthetic outcomes and PROs is complex. Limited available evidence 
suggests that OPS has a modest impact on patient satisfaction.59 An observational study from Brazil 
found a significantly higher proportion of excellent results after OPS compared to conventional BCS 
when measured by software and surgeons. However, there were no differences when assessed by 
patients.60 There are at least ten commonly used PRO metrics in breast surgery, and new tools are 
currently under development.61-63 Determination of the best assessment tool will facilitate QoL 
measurements across OPBC centres in future studies, but in the meantime, the panel recommended the 
BREAST-Q for addressing the above knowledge gaps as this is one of the most widely used and 
comprehensive PRO instruments. It is rigorously developed, validated, specific to breast surgery and 
available in several languages.64-66 Despite there being no universally accepted approach for 
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determining the clinical significance of health-related QoL data, first estimates on minimally 
important differences for the BREAST-Q scores have now been published and these allow sample size 
calculations for clinical trials.67  
Clinical indicators of risk in OPS are likely to focus on factors such as rates of complications and 
return to the operating room as well as delays to start of adjuvant treatments or return to work. A 
comprehensive review showed high rates of overall and disease-free survival together with low rates 
of local recurrence, positive margins and re-excisions after OPS. Thus, conventional oncologic 
parameters do not seem to be discriminatory as critical quality indicators.68 Another large review 
found a wide range of complications after OPS with largely differing risk based on poorly designed 
and underpowered studies.4 The lack of current standards in OPS hampers clinical research in this 
field. Even though the knowledge gaps referring to OPS classifications systems were ranked low (27th 
and 30th) in the present Delphi process, the need for standardisation of OPS in clinical research and 
practice is widely accepted. 10,69-72 The specific risks associated with various techniques need to be 
determined to support the development of quality assurance programmes for OPS.  
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Conclusion 
The 2019 OPBC Delphi process and consensus conference resulted in the following recommendations: 
Firstly, the optimal type and timing of reconstruction after NSM/SSM with planned radiotherapy 
should be addressed by prospective cohort studies at an international level. Secondly, the role of 
adjunctive mesh and the positioning of implants during IBBR should ideally be investigated by RCTs 
of pragmatic design. Thirdly, the impact of OPS on quality of life should be investigated. While  
. BREAST-Q is a suitable tool to assess primary outcomes in these studies, other PRO metrics should 
be systematically evaluated and quality indicators of surgical morbidity further assessed.  
The consensus conference panel recognised significant overlap between the prioritised knowledge 
gaps. It reinforced an earlier recommendation to implement a prospective register based on a defined 
set of core variables for oncoplastic procedures at OPBC centres.11 Future observational OPBC studies 
can be embedded in this register, which will also permit the feasibility of any particular RCT to be 
promptly assessed by real life data from the study sites.   
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Figure 1: Right oncoplastic reduction mammoplasty with inferior pedicle for supraareolar tumour and 
left reduction mammoplasty for symmetry 
 
A: Procedure at a glance 
 
B: Patient before surgery with preoperative marking of tumour, landmarks and new position of the 
nipple 
 
C: Right oncoplastic supraareolar en bloc tumorectomy 
 
D: Bilateral reduction mammoplasty with inferior pedicle 
 
E: Patient one year after surgery  
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Table 1: Final ranking of knowledge gaps in oncoplastic surgery 
prioritised during the Delphi process  
Recommendation 
rate* 
Likert scale         
mean rating† 
(1) What is the optimal type of reconstruction in the setting of planned adjuvant radiotherapy? 60.9% 7 
(2) What is the optimal timing of reconstruction in the setting of planned adjuvant radiotherapy? 57.1% 7 
(3) What is the effect of OPS on local recurrence risk? 48.9% 7.5 
(4) What is the effect of modern radiotherapy on local recurrence risk after OPS in general and the 
role of partial irradiation and radiotherapy boost, when larger margins are achieved, in particular? 
47.8% 7.5 
(5) What are the indications for the use of synthetic versus biological versus no mesh in implant-
based breast reconstruction (IBBR)? 
47.8% 7 
(6) What are the indications for the use of pre- vs sub-pectoral IBBR? 47.7% 7.5 
(7) What is the effect of OPS on quality of life? 42.8% 7.5 
(8) What is the clinical relevance of breast implant associated-anaplastic large cell lymphoma? 35.2% 7 
(9) What are the best tools to measure the effect of OPS on quality of life and to allow comparison 
of trial results? 
34.3% 7 
(10) What are the indications for the use of one- vs two-stage IBBR?‡  32.8% 6.75 
(11) What are contraindications for nipple preservation? 32.4% 7 
(12) What are the most accurate quality indicators in OPS? 29.8% 7 
(13) What are the best localisation techniques for non-palpable tumours in OPS? 28.1% 6.5 
(14) What are the indications for contralateral prophylactic mastectomy?‡ §  26.9% 7 
(15) What are the advantages of OPS compared to conventional breast conserving surgery?¶  24.3% 7 
  
(16) What are the indications for risk-reducing surgery? 23.3% 7 
(17) Is NSM/SSM oncologically safe when used for locally advanced breast cancer without the use 
of neoadjuvant chemotherapy?||  
22.2% 6 
(18) What is the impact of surgical technology on risk of skin flap necrosis (scalpel/scissors vs 
electrocautery vs Plasma Blade)? 
19.8% 6 
(19) What are contraindications for skin preservation? 19.5% 7 
(20) What is the role of surgical axillary staging in risk-reducing NSM/SSM?||  18.9% 6 
(21) How can we coordinate training efforts in OPS?** 18.3% 7 
(22) What is the best technique for intraoperative skin flap viability assessment to reduce the risk 
of skin flap necrosis (e.g., indocyanine green fluorescence, thermography)? 
17.4% 5.5 
(23) What is the optimal site of incision in specific situations (e.g., tumour <1cm from the nipple, 
upper-inner quadrant tumour in large breast)? 
16.9% 6 
(24) What is the optimal follow-up (interval, imaging modality) for patients after NSM? 15.9% 7 
(25) Does the immediate use of compression bra or compression dressing reduce the risk of skin 
flap necrosis? 
15.8% 5.5 
(26) What is the optimal treatment of a positive retroareolar margin? 15.0% 7 
(27) How can we optimise current OPS classification systems for use in clinical research? 14.7% 7 
(28) What is the role of robotic surgery for NSM? 14.6% 4.75 
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(29) What is the best treatment of non-infectious skin breakdown after IBBR? 13.8% 6.5 
(30) What are the best OPS classification systems for use in clinical practice by professionals and 
insurance companies? 
13.6% 6.5 
(31) Should follow-up after risk reducing NSM/SSM be individualised according to the amount of 
residual breast tissue on imaging? 
13.0% 6 
(32) What is the optimal timing for contralateral symmetrising procedures? 12.1% 7 
(33) What is the role of MRI before NSM? 11.9% 7 
(34) What is the optimal follow-up (interval, imaging modality) for patients after SSM? 11.0% 6.75 
(35) What is the best treatment for implant-related cellulitis? 10.5% 6 
(36) What are the indications for retroareolar frozen section? 8.6% 6 
(37) What is the best technique for tissue conditioning to reduce the risk of skin flap necrosis (e.g., 
nitroglycerine and/or local heat application)? 
6.6% 5.5 
(38) Should NSM be performed in male patients with breast cancer? 5.2% 5 
* Recommendation to discuss this knowledge gap at the consensus conference.                                                                                                                                        
† Ranking of importance of every knowledge gap on a 9-point Likert scale from 1 (not important) to 9 (extremely important). Importance 
was defined as the urgent need of knowledge to guide clinical practice and research.                                                                                                                                                                         
‡ This question was not ranked among the 15 most important knowledge gaps by patient advocates, but was included due to high ranking 
by medical professionals.                                                                                                                                                                                                                                                           
§ This question was included in the 15 most important knowledge gaps by reprioritisation during the 2nd Delphi round.                                                                                                
¶  This question was not ranked among the 15 most important knowledge gaps by medical professionals, but was included due to high 
ranking by patient advocates.                                                                                                                                                                                                                                                        
|| Dropped out of the 15 most important knowledge gaps due to low ranking by medical professionals.                                                                                                                                                                                   
** Dropped out of the 15 most important knowledge gaps due to low ranking by patient advocates.  
OPS  Oncoplastic breast-conserving surgery 
NSM  Nipple-sparing mastectomy 
SSM  Skin-sparing mastectomy 
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Table 2: Selection of research priorities from the 15 most important knowledge gaps by the 
OPBC panel 
  
  
  
  
  
Knowledge gaps No. of 
votes 
Yes  No  Abstain Final 
recommendation* 
  Results of final voting   
(1) What is the optimal type of reconstruction in the setting of 
planned adjuvant radiotherapy? 
59 58 1 0 98% (Consensus) 
(2) What is the optimal timing of reconstruction in the setting of 
planned adjuvant radiotherapy? 
60 51 6 3 85% (Consensus)  
(3) What is the effect of OPS on local recurrence risk? 59 26 31 2 44% (No 
Consensus)  
(4) What is the effect of modern radiotherapy on local recurrence risk 
after OPS in general and the role of partial irradiation and radiotherapy 
boost, when larger margins are achieved, in particular?‡  
60  26 31 3 43% (No 
Consensus) 
(5) What are the indications for use of synthetic versus biological 
versus no mesh in implant-based breast reconstruction (IBBR)? 
58 50 8 0 86% (Consensus) 
(6) What are the indications for use of pre- vs sub-pectoral IBBR? 60 52 3 5 87% (Consensus) 
(7) What is the effect of OPS on quality of life? 59 56 3 0 95% (Consensus) 
(8) What is the clinical relevance of breast implant associated-
anaplastic large cell lymphoma?‡  
60 42 17 1 70% (Majority) 
(9) What are the best tools to measure the effect of OPS on quality 
of life and to allow comparison of trial results? 
60 51 7 2 85% (Consensus) 
(10) What are the indications for the use of one- vs two-stage IBBR?‡  59 40 18 1 68% (Majority) 
(11) What are contraindications for nipple preservation?‡  59 39 18 2 66% (Majority) 
(12) What are the most accurate quality indicators in OPS? 58 46 12 0 79% (Consensus)  
(13) What are the best localisation techniques for non-palpable tumours 
in OPS? 
59 15 41 3 25% (No 
Consensus) 
(14) What are the indications for contralateral prophylactic 
mastectomy?‡  
59 28 31 0 47% (No 
Consensus)  
(15) What are the advantages of OPS compared to conventional breast-
conserving surgery?‡  
60 41 18 1 68% (Majority) 
* Recommendation to include this knowledge gap in the OPBC research agenda based on its importance. Majority was defined by 
agreement among 51–75% of the panellists and consensus by agreement above 75%. Importance was defined as the urgent need of 
knowledge to guide clinical practice and research.                                                                                                                                                                                                                  
‡ As pre-specified in the protocol, discussion and re-voting were encouraged in case of initial majority voting (supplementary appendix 1). 
OPS  Oncoplastic breast-conserving  surgery                                                                                                                                                                                                                                                                                                                                                               
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Table 3: Research priorities with corresponding research question and study design as 
recommended by the OPBC panel during the consensus conference 
Research 
priorities 
Research question in PICO 
format 
Study Design 
No. of 
votes 
Yes  No  Abstain 
Final 
voting 
What is the optimal 
type of 
reconstruction in 
the setting of 
planned adjuvant 
radiotherapy? 
P: Are breast cancer patients with 
planned radiotherapy                                                                     
I: with immediate pre-pectoral 
implant, radiation, exchange to 
autologous reconstruction                                                                
C: compared to  immediate 
autologous reconstruction                                                                        
O: more satisfied with the 
reconstructed breast at two years 
after mastectomy 
- Prospective cohort study                                                                                        
- Propensity score matching                                                                                     
- 2 years follow-up                                                 
- Primary outcome: 
Satisfaction with breast
(BREAST-Q)                                                                       
58 46 11 1 79%
(Consensus) 
What is the optimal 
timing of 
reconstruction in 
the setting of 
planned adjuvant 
radiotherapy? 
P: Are patients with breast cancer 
who require mastectomy and will 
need PMRT                                                                         
I: with immediate reconstruction 
(stratified by technique)                                                             
C: compared to delayed 
reconstruction (could have 
temporary expander)                                                                          
O: more satisfied with breasts? 
- Prospective register                                            
- 2 years follow-up                                                
- Primary outcome: 
Satisfaction with breast 
(BREAST-Q) 
                                                                                                              
  
57 47 7 3 82% 
(Consensus)  
What are the 
indications for use 
of synthetic versus 
biological versus 
no mesh in 
implant-based 
breast 
reconstruction 
(IBBR)? 
P: Are patients after mastectomy 
receiving                                
I: immediate pre-pectoral implant 
reconstruction without ADM or 
synthetic mesh                                                                      
C: compared to pre-pectoral implant 
reconstruction with ADM or 
synthetic mesh                                                                      
O: less satisfied with the 
reconstructed breast? 
- Pragmatic RCT                                                   
- 1:1 Randomisation                                              
- 3 years follow-up                                               
- Primary outcome: 
Satisfaction with breast 
(BREAST-Q)                                                        
- Non-inferiority 
57 40 12 5 70% 
(Majority)  
What are the 
indications for the 
use of pre- vs sub-
pectoral IBBR? 
P: Are patients after mastectomy 
receiving                                
I: immediate pre-pectoral implant 
reconstruction                       
C: compared to immediate sub-
pectoral implant reconstruction                                                       
O: more satisfied with the 
reconstructed breast? 
- Pragmatic RCT                                                      
- 1:1 Randomisation                                             
- 2 years follow-up                                               
- Primary outcome: 
Satisfaction with breast  
(BREAST-Q)                                    
- Superiority  
56 47 5 4 84% 
(Consensus) 
 What is the effect 
of OPS on quality 
of life? 
P: Are patients after                                                                   
I: level II* OPS                                                                         
C: compared to standard BCS and 
mastectomy                       
O: more satisfied with their breasts? 
- Prospective multi-centre 
cohort study                                          
- Primary endpoint: 
Satisfaction with breast 
(BREAST-Q)                                                      
- Propensity matching   
55 53 2 0 96% 
(Consensus) 
What are the best 
tools to measure 
the effect of OPS 
on quality of life 
and to allow 
comparison of trial 
results? 
P: What are the best tools to 
measure the effect of OPS on 
quality of life and to allow 
comparison of trial results? 
- Systematic review / meta-
analysis                    
- Delphi including patients                                 
- Consensus conference 
with patients 
                                                                                                              
  
58 44 8 6 76% 
(Consensus)  
(What are the most 
accurate quality 
indicators in OPS? 
P: Do patients after                                                                    
I: OPS                                                                                        
C: compared to standard BCS or 
mastectomy                           
O: experience more complications? 
- Prospective multi-centre 
cohort study                                         
- Endpoints: complication 
rate, sick leave, return to 
work, return to theatre 
58 52 6 0 90% 
(Consensus)  
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* according to the classification by Clough et al 
  
ADM  Acellular Dermal Matrix  
BCS Breast-conserving surgery 
IBBR Implant-based breast reconstruction  
OPS Oncoplastic breast-conserving surgery 
PICO  Population, Intervention, Comparison, Outcome 
PMRT Post-mastectomy radiotherapy 
RCT  Randomised controlled trial 
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